research Atypical bilateral hyperpigmented macules on the lower legs possibly due to cyclophosphamide.
Cyclophosphamide likely causes skin darkening by affecting hair follicles.
Search
forProducts matching "pyrilutamide kx-826"
Tracking 3 products like 259 Pyrilutamide (KX-826) Solution – 30ml 5mg/ml, 262 Pyrilutamide KX-826 Powder – 500mg and 379 KX-826 DHT Blocker Hair Thickening,3 Days Oil Control from by companies like Anageninc and Amazon. View all 3 products »
Sort by
Research
570-600 / 1000+ results
research Identification of neprilysin as a potential target of arteannuin using computational drug repositioning
Arteannuin might work against cancer and Alzheimer's by targeting neprilysin.
research Logic-based modeling and drug repurposing for the prediction of novel therapeutic targets and combination regimens against E2F1-driven melanoma progression
Tadalafil and Finasteride may help treat aggressive melanoma.
research NUDT15,FTO, andRUNX1genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases
Genotyping for NUDT15 p.Arg139Cys can help predict thiopurine side effects in Japanese IBD patients.
research Logic-Based Modeling and Drug Repurposing for the Prediction of Novel Therapeutic Targets and Combination Regimens against E2F1-Driven Melanoma Progression
Cialis and Finasteride could be repurposed to treat aggressive melanoma.
research Aromatase inhibition by letrozole attenuates kainic acid-induced seizures but not neurotoxicity in mice
Letrozole reduces seizures but not brain damage in mice.
research Finasteride blocks progesterone synthesis in MA-10 Leydig tumor cells
research NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
research Therapeutic Effect of Platelet-Rich Plasma Improves Bladder Overactivity in the Pathogenesis of Ketamine-Induced Ulcerative Cystitis in a Rat Model
Platelet-rich plasma improves bladder function and reduces overactivity in ketamine-induced bladder issues.
research ODP056 The Treatment of Opioid Addiction Leading to Secondary Adrenal Insufficiency
Long-term treatment with buprenorphine/naloxone for opioid addiction may lead to secondary adrenal insufficiency.
research Synthesis, antiproliferative activity, acute toxicity and assessment of the antiandrogenic activities of new androstane derivatives
research A method for simultaneous analysis of androgens, dutasteride and finasteride in human serum by liquid chromatography tandem mass spectrometry
A new method was developed to analyze certain hormones and drugs in human blood efficiently.
research Synthesis, antiproliferative, acute toxicity and assessment of antiandrogenic activities of some newly synthesized steroidal lactams
research Non-competitive androgen receptor inhibition in vitro and in vivo
Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.
research Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride
Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.
research Reporting on Adverse Clinical Events
Some medications and supplements can cause serious side effects, including hair loss, heart rhythm problems, liver injury, and other health issues.
research In silico investigation of possible multi-target drugs against Glutamate S-transferase and prolyl tRNA synthetase in Onchocerca volvulus
Bedaquiline, Telmisartan, Diosmin, Azelastine, and Adapalene may be effective treatments for onchocerciasis.
research An urticarial drug eruption caused by tofacitinib for alopecia universalis
A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
research PHARMACOLOGICAL BASIS FOR CLINICAL USE OF ANTIANDROGENS
Cyproterone acetate is used to treat conditions like prostate cancer, early puberty, excessive sexual drive, and female androgenization by affecting androgen functions and suppressing certain hormones.
research 11 Treatment of hirsutism and acne with cyproterone acetate
Cyproterone acetate is effective for treating hirsutism and acne but less so for hair loss, with side effects similar to birth control pills.
research Highlights from JAAD Reviews: August 2025—Bicalutamide for female hair loss
Bicalutamide shows promise for treating female hair loss.
research XMU-MP-1 induces growth arrest in a model human mini-organ and antagonises cell cycle-dependent paclitaxel cytotoxicity
XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.
research Compatibility of Cetirizine Hydrochloride, Dutasteride, Hydrocortisone Acetate, Nicotinamide, Progesterone, and Pyridoxine Hydrochloride in TrichoSolTM, A Natural Vehicle for Hair Solutions.
TrichoSolTM is safe for hair loss treatments with specific ingredient stability for up to 180 days.
research Development and validation of a new gas flame ionization detector method for the determination of finasteride in tablets
New method accurately measures finasteride in tablets.
research Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies
research HPLC-APCI-MS Determination of Finasteride in Human Plasma
The method accurately measures finasteride in human plasma quickly and reliably.
research Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study
High doses of cyproterone acetate increase the risk of brain tumors in women, but the risk decreases after stopping the medication.
research Finasteride/spironolactone
research Vandetanib
A man developed alopecia areata after starting cancer treatment with vandetanib.
research A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata
Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.